[Immunotherapy with interleukin-2 and allogenic LAK cells in a patient with acute myeloblastic leukemia].
At the present time the effectiveness of interleukin-2 (IL-2) administered together with IL-2 in vitro activated lymphocytes (LAK) in the treatment of malignant neoplasias is being assessed. We report the case of an 8 -year- old patient suffering from acute myeloid leukemia (AML) who had relapsed from an autologous bone marrow transplant (ABMT) and received a second ABMT in partial remission. After the second ABMT, the patient, who entered into a phase of complete remission (CR) but with a severe thrombocytopenia, was treated with IL-2 and allogeneic LAK cells obtained from his father. During treatment the lymphocyte subpopulations and cytolytic activity were assayed. Increases in the patient's lymphocytes with CD3- CD4- CD8- CD16+, CD3- CD4- CD8- CD56+, CD3- CD4- CD8+ CD56+ and CD3- CD4- CD8+ CD56+ phenotypes were observed and these were correlated with cytolytic activity measured against the K562 cell line. The patient remained in CR for longer (14 months) than after the first ABMT (5 months). The immune activation produced by this therapy could have had an antileukemic effect in the patient.
Parrado
A
A
Servicio de Hematología y Hemoterapia, Hospital Universitario Virgen del Rocío, Sevilla.
Casares
S
S
Carmona
M
M
Campo
T
T
Rodríguez Fernández
J M
JM
D002648:Child; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male
D007376:Interleukin-2
Inmunoterapia con interleucina-2 y células LAK alogénicas en un paciente con leucemia aguda mieloblástica.